content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Fate Therapeutics, Inc. (FATE)

11.20
0.14
(1.27%)
 Sep 11, 4:00PM EDT
content_middle

Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.

FATE’s immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors.

FATE's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.

Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells.

Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Company Website
Previous Close: 
4.12
Open: 
4.12
Bid: 
3.56
Ask: 
4.80
1yr Target Price: 
7.67
Day's Range: 
3.99 - 4.29
52wk Range: 
2.81 - 14.45
Volume: 
328156
Average Daily Volume: 
286267
Market Capitalization: 
598.29M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
53.42M
content_right

Pages